AUSTRALIAN CLINICAL LABS LIMITEDAUSTRALIAN CLINICAL LABS LIMITEDAUSTRALIAN CLINICAL LABS LIMITED

AUSTRALIAN CLINICAL LABS LIMITED

No trades
See on Supercharts

Price target

3.530.000.00%
The 4 analysts offering 1 year price forecasts for ACL have a max estimate of — and a min estimate of —.

Analyst rating

Based on 6 analysts giving stock ratings to ACL in the past 3 months.

EPS

Reported
Estimate
Reported
Estimate
Surprise

Revenue

Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


ACL EPS for the last quarter is 0.11 AUD despite the estimation of 0.08 AUD. In the next quarter EPS is expected to reach 0.08 AUD. Track more of AUSTRALIAN CLINICAL LABS LIMITED financials and stay on top of what is up with the company.
In the next quarter AUSTRALIAN CLINICAL LABS LIMITED revenue is expected to reach ‪361.70 M‬ AUD. Check out AUSTRALIAN CLINICAL LABS LIMITED revenue and earnings and make informed decisions.
According to analysts, ACL price target is 3.53 AUD with a max estimate of 3.90 AUD and a min estimate of 2.95 AUD. Check if this forecast comes true in a year, meanwhile watch AUSTRALIAN CLINICAL LABS LIMITED stock price chart and keep track of the current situation with ACL news and stock market news.
We've gathered opinions of 6 analysts rating ACL stock in the past 3 months. After counting all points of view, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.